DNMT1 and myelodysplastic syndrome: To test this hypothesis, we treated 152M cells with the general DNMT inhibitor Decitabine (5-Aza-2′-deoxycytidine), which is a Food and Drug Administration (FDA)-approved drug for therapy of myelodysplastic syndromes (MDS) [41].